Idec beats Street EPS

As expected, IDPH reported third quarter EPS of $0.30, $0.03 above the consensus EPS estimate (see BioCentury Extra, Wednesday Oct. 11). U.S. sales of Rituxan, from which IDPH receives royalties, cam...